JP2017531659A5 - - Google Patents

Download PDF

Info

Publication number
JP2017531659A5
JP2017531659A5 JP2017518466A JP2017518466A JP2017531659A5 JP 2017531659 A5 JP2017531659 A5 JP 2017531659A5 JP 2017518466 A JP2017518466 A JP 2017518466A JP 2017518466 A JP2017518466 A JP 2017518466A JP 2017531659 A5 JP2017531659 A5 JP 2017531659A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
factor
composition according
colloidal particles
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017518466A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017531659A (ja
Filing date
Publication date
Priority claimed from GBGB1417589.7A external-priority patent/GB201417589D0/en
Application filed filed Critical
Publication of JP2017531659A publication Critical patent/JP2017531659A/ja
Publication of JP2017531659A5 publication Critical patent/JP2017531659A5/ja
Pending legal-status Critical Current

Links

JP2017518466A 2014-10-06 2015-10-06 Peg化リポソームおよび血液凝固因子の製剤処方 Pending JP2017531659A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1417589.7 2014-10-06
GBGB1417589.7A GB201417589D0 (en) 2014-10-06 2014-10-06 Pharmaceutical Formulations
PCT/EP2015/073003 WO2016055447A1 (en) 2014-10-06 2015-10-06 Pharmaceutical formulations of pegylated liposomes and blood coagulation factors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020129101A Division JP2020183446A (ja) 2014-10-06 2020-07-30 Peg化リポソームおよび血液凝固因子の製剤処方

Publications (2)

Publication Number Publication Date
JP2017531659A JP2017531659A (ja) 2017-10-26
JP2017531659A5 true JP2017531659A5 (cg-RX-API-DMAC7.html) 2018-11-15

Family

ID=51946871

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017518466A Pending JP2017531659A (ja) 2014-10-06 2015-10-06 Peg化リポソームおよび血液凝固因子の製剤処方
JP2020129101A Pending JP2020183446A (ja) 2014-10-06 2020-07-30 Peg化リポソームおよび血液凝固因子の製剤処方
JP2022168146A Active JP7573582B2 (ja) 2014-10-06 2022-10-20 Peg化リポソームおよび血液凝固因子の製剤処方

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020129101A Pending JP2020183446A (ja) 2014-10-06 2020-07-30 Peg化リポソームおよび血液凝固因子の製剤処方
JP2022168146A Active JP7573582B2 (ja) 2014-10-06 2022-10-20 Peg化リポソームおよび血液凝固因子の製剤処方

Country Status (16)

Country Link
US (2) US20170304203A1 (cg-RX-API-DMAC7.html)
EP (1) EP3204034B9 (cg-RX-API-DMAC7.html)
JP (3) JP2017531659A (cg-RX-API-DMAC7.html)
AU (1) AU2015330102B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017007031A2 (cg-RX-API-DMAC7.html)
CA (1) CA2994891C (cg-RX-API-DMAC7.html)
ES (1) ES2954134T3 (cg-RX-API-DMAC7.html)
GB (1) GB201417589D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20230985T1 (cg-RX-API-DMAC7.html)
HU (1) HUE063656T2 (cg-RX-API-DMAC7.html)
MX (1) MX384517B (cg-RX-API-DMAC7.html)
PL (1) PL3204034T3 (cg-RX-API-DMAC7.html)
RS (1) RS64461B1 (cg-RX-API-DMAC7.html)
RU (1) RU2737291C2 (cg-RX-API-DMAC7.html)
SM (1) SMT202300271T1 (cg-RX-API-DMAC7.html)
WO (1) WO2016055447A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201417589D0 (en) * 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
JP6825010B2 (ja) * 2016-05-26 2021-02-03 ベクトン・ディキンソン・アンド・カンパニーBecton, Dickinson And Company 遠心法によるリポソーム調製のための方法及び装置

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US6326353B1 (en) 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method
ATE179599T1 (de) 1993-08-06 1999-05-15 Opperbas Holding Bv Verfahren zur hohen beladung von vesikeln mit biopolymeren substanzen
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
US6156337A (en) * 1994-07-08 2000-12-05 Opperbas Holding B.V. Method for high loading of vesicles with biopolymeric substances
US6310183B1 (en) * 1997-09-10 2001-10-30 Novo Nordisk A/S Coagulation factor VIIa composition
ES2233036T3 (es) * 1998-04-27 2005-06-01 Opperbas Holding B.V. Composicion farmaceutica que comprende factor viii y liposomas neutros.
RU2250911C2 (ru) 1999-07-14 2005-04-27 Элзэ Копэрейшн Липосомальная композиция, нейтральный липополимер и способ увеличения времени циркуляции липосомы
JP5090605B2 (ja) * 2000-05-03 2012-12-05 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 凝固因子viiの皮下投与
US20070141135A1 (en) 2005-06-29 2007-06-21 Balu-Lyer Sathy V Compositions and methods for less immunogenic protein-lipid complexes
US20030232075A1 (en) 2002-05-06 2003-12-18 University Of Minnesota, A Minnesota Corporation Compositions for producing factor Xa
ATE395101T1 (de) * 2003-04-15 2008-05-15 Opperbas Holding Bv Pharmazeutische zusammensetzung, enthaltend proteine und/oder polypeptide sowie kolloidpartikel
WO2008081024A1 (en) * 2007-01-03 2008-07-10 Novo Nordisk Health Care Ag Subcutaneous administration of coagulation factor viia-related popypeptdes
CA2701884A1 (en) 2007-10-15 2009-04-23 Wake Forest University Health Sciences Methods and compositions for printing biologically compatible nanotube composites of autologous tissue
EP2437726B1 (en) 2009-06-03 2018-05-16 Sequessome Technology Holdings Limited Formulations for the treatment of deep tissue pain
AU2010283998B2 (en) 2009-08-21 2015-01-29 Targeted Delivery Technologies Limited Vesicular formulations
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
GB201007357D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
TW201240664A (en) * 2010-09-01 2012-10-16 Portola Pharm Inc Methods and formulations of treating thrombosis with betrixaban and a P-glycoprotein inhibitor
GB2516388A (en) * 2012-04-16 2015-01-21 Cantab Biopharmaceuticals Patents Ltd Optimised subcutaneous therapeutic agents
GB201417589D0 (en) * 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations

Similar Documents

Publication Publication Date Title
Montazerian et al. Engineered hemostatic biomaterials for sealing wounds
Rajkumar et al. Chitosan-based biomaterial in wound healing: a review
Huang et al. Degradable and bioadhesive alginate-based composites: an effective hemostatic agent
CN103687631B (zh) 促凝血肽及其衍生物以及它们的用途
Dong et al. Injectable adhesive hydrogel through a microcapsule cross-link for periodontitis treatment
JP2020073617A (ja) 免疫療法のための調節粒子
JP2015527391A (ja) ヒアルロン酸をベースとする薬物送達システム
JP2014533988A5 (cg-RX-API-DMAC7.html)
Chan et al. Synthetic strategies for engineering intravenous hemostats
JP2002512947A5 (cg-RX-API-DMAC7.html)
JP2012025955A5 (cg-RX-API-DMAC7.html)
JP2014530066A5 (cg-RX-API-DMAC7.html)
WO2023231051A1 (zh) 一种用于治疗糖尿病创面的抗菌抗氧化水凝胶敷料及其制备方法
CN107027292A (zh) 均匀膜组合物
CN103189078A (zh) 含有透明质酸和l-精氨酸的抗粘连剂
Fan et al. Superhydrophilic PLGA-graft-PVP/PC nanofiber membranes for the prevention of epidural adhesion
Joo et al. Fibrinogen as a promising material for various biomedical applications
JP2017531659A5 (cg-RX-API-DMAC7.html)
JP2018535952A5 (cg-RX-API-DMAC7.html)
Guo et al. Periodontium-mimicking, multifunctional biomass-based hydrogel promotes full-course socket healing
ES2657901T3 (es) Utilidad ampliada de las micropartículas derivadas de glóbulos rojos (RMP) para el tratamiento de la hemorragia
RU2017115831A (ru) Фармацевтические составы пегилированных липосом и факторов свертывания крови
WO2019152766A1 (en) Antimicrobial platelet-like particles
JP5889188B2 (ja) 組織接着用シート製剤
KR20160118624A (ko) 유착 방지제